** charts before earnings **
GoodRx beats by $0.03, beats on revs; guides Q4 revs below consensus
- Reports Q3 (Sep) earnings of $0.07 per share, excluding non-recurring items, $0.03 better than the S&P Capital IQ Consensus of $0.04; revenues fell 4.0% year/year to $187.32 mln vs the $185.01 mln S&P Capital IQ Consensus.
- Co issues downside guidance for Q4, sees Q4 revs of $175-$180 mln vs. $204.86 mln S&P Capital IQ Consensus.
- "Our focus on Adjusted EBITDA growth, margin improvement, and cash conversion remain our top priorities," said Karsten Voermann, Chief Financial Officer. "We are guiding to fourth quarter total revenue in the range of $175 million to $180 million, which includes a combined $45 million to $50 million estimated impact to prescription transactions revenue related to the previously disclosed grocer issue and our continued consumer engagement efforts. We expect Adjusted EBITDA Margins in the low-to-mid-twenty-percent range."
No comments:
Post a Comment